- Home
- Megavog MF 0.2/500 Tablet
Megavog MF 0.2/500 Tablet Substitute
Megavog MF 0.2/500 Tablet Substitute
Verified Ingredients and Effects
Composition:
METFORMIN-500MG + VOGLIBOSE-0.2MG
Uses:
<p>Megavog MF 0.2/500 Tablet is used in the treatment of type 2 diabetes mellitus. The detailed uses of Megavog MF 0.2/500 Tablet are as follows: &lt;br/&gt; • Management of type 2 diabetes mellitus: Helps control high blood sugar levels in adults with type 2 diabetes.&lt;br/&gt; • Improves insulin sensitivity: Metformin enhances the body's response to insulin and reduces glucose production by the liver.&lt;br/&gt; • Delays glucose absorption: Voglibose reduces the breakdown and absorption of carbohydrates in the intestine, thereby avoiding post-meal sugar spikes.&lt;br/&gt; • Reduces risk of diabetes complications: Megavog MF 0.2/500 Tablet helps reduce the risk of kidney damage, nerve disorders, and vision problems that can result from uncontrolled blood sugar levels.&lt;br/&gt;</p>
Medicinal Benefits:
Megavog MF 0.2/500 Tablet is used to treat type 2 diabetes mellitus. It is a combination of Voglibose and Metformin. Voglibose belongs to the class of alpha-glucosidase inhibitors. It delays glucose absorption by inhibiting the intestinal enzymes, which break complex sugars into simple sugars such as glucose. This process prevents the rise of blood glucose levels immediately after meals. Metformin belongs to the class of biguanides. It demonstrates the non-pancreatic effect of reducing serum glucose levels without increasing insulin secretion. It is also known as an insulin sensitiser as it increases the effects of insulin. Together, Megavog MF 0.2/500 Tablet helps treat diabetes mellitus type 2.
FAQs
Megavog MF 0.2/500 Tablet is used in the treatment of type 2 diabetes mellitus.
Megavog MF 0.2/500 Tablet contains two antidiabetic drugs, namely: Voglibose and Metformin. Voglibose delays glucose absorption by inhibiting the intestinal enzymes, which break complex sugars into simple sugars such as glucose. Metformin works by reducing the sugar production by cells in the liver and delaying sugar absorption from the intestines. Together, Megavog MF 0.2/500 Tablet helps treat type 2 diabetes.
There is no evidence of Megavog MF 0.2/500 Tablet , causing weight loss. However, it may cause a loss of appetite, leading to weight loss. Consult your doctor if you have any concerns.
Megavog MF 0.2/500 Tablet may increase the risk of low blood sugar levels, especially when combined with alcohol intake, increased exercise, or skipping or delaying snacks or meals. However, if you experience any signs of low blood sugar, such as dizziness, nausea, light-headedness, dehydration or fainting, please consult a doctor.
You are not recommended to stop taking Megavog MF 0.2/500 Tablet on your own, as discontinuing Megavog MF 0.2/500 Tablet suddenly may cause an increase in blood sugar levels or worsen the condition. However, if you experience any difficulty while taking Megavog MF 0.2/500 Tablet , please consult your doctor so that alternative medicine may be prescribed.